Pipeline

Sorrento's R&D tau tsom mus rau kev tsav tsheb tshiab hauv COVID-19, kev kho mob qog noj ntshav, kev tswj mob tag nrho thiab kab mob autoimmune.

Cov Txheej Txheem Tseem Ceeb Kev qhia Peb muaj Theem I Qis II Phase III/Pivotal Tso Cai FDA
Cov kev pab cuam COVID-19  

COVISTIX™ (kev kuaj mob) Rapid Antigen Test

*

Kev Tso Cai Siv Thaum Muaj Xwm Ceev (EUA) hauv Mexico (COFEPRIS), Brazil (ANVISA), thiab CE Marked hauv Tebchaws Europe

COVIMARK™ (kev kuaj mob) Rapid Antigen Test

*

Daim ntawv thov xa hauv Asmeskas thiab Canada rau Kev Tso Cai Siv Thaum Muaj Xwm Ceev (EUA)

VIREX (kev kuaj mob) Hauv Tsev Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (kev kho mob) Neutralizing Antibody (IV) hauv cov neeg mob sab nraud thiab cov neeg mob hauv tsev

20%*

FUJOVEE™ (Abivertinib) Tus mob hnyav COVID-19 hauv ICU Cov Neeg Mob

82%*

Pivotal Trial Pending FDA Clearance

OQORY™ (COV-MSC) ARDS vim yog COVID-19 hauv ICU Cov Neeg Mob

82%*

Pivotal Trial hauv Brazil

Mpro Inhibitor (qhov ncauj ntsiav tshuaj) Anti-kis

40%*

Omicron mRNA tshuaj tiv thaiv Tshuaj Tiv Thaiv

20%*

Cov Txheej Txheem Tseem Ceeb Kev qhia Peb muaj Theem I Qis II Phase III/Pivotal Tso Cai FDA
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) prostate

20%*

FUJOVEE™ (Abivertinib) lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab) * SCLC

82%*

* Hauv kev koom tes nrog Lee's Pharm hauv Suav teb

PD-L1 (STI-3031) ncauj tsev menyuam Cancer

82%*

** Hauv Asmeskas thiab koom tes nrog ImmuneOncia hauv Kaus Lim Kauslim

CD47 Cov qog nqaij hlav

40%*

CD38 DAR-T Ntau yam mob Myeloma

40%*

CD38 ADC Amyloidosis, Ntau Myeloma, T-ALL, thiab esophageal

40%*

Seprehvec™ oncolytic virus Cov qog nqaij hlav; CNS qog

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADNAB™ Endometrial Cancer

40%*

Hauv kev koom tes nrog Mayo Clinic

Bevacizumab-ADNAB™ Cancer ntawm pojniam

40%*

Hauv kev koom tes nrog Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Hauv kev koom tes nrog Mayo Clinic

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Cov Txheej Txheem Tseem Ceeb Kev qhia Peb muaj Theem I Qis II Phase III/Pivotal Tso Cai FDA
mob  

ZTlido® 1.8%
Postherpetic Neuralgia - PHN

99.8%*

Gloperba®
Kev kho mob ntawm Gout (Qhov ncauj)

99.8%*

SEMDEXA (SP-102) Lumbar Radicular / Sciatica Mob

82%*

SP-103 (Lidocaine Topical System 5.4%) Mob Mob Siab

60.2%*

SP-104 (Delayed Burst Low Dose Naltrexone) fibromyalgia

20%*

RTX (resiniferatoxin)
Kev txhaj tshuaj Epidural
Intractable Mob nyob rau hauv Advanced Cancer

60.3%*

Orphan npe

RTX (resiniferatoxin)
Intra-articular txoj kev
Nruab nrab mus rau Hneev OA Mob

60.2%*

Cov Txheej Txheem Tseem Ceeb Kev qhia Peb muaj Theem I Qis II Phase III/Pivotal Tso Cai FDA
Lymphatic Drug Delivery  

Sofusa® tiv thaiv TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

Hauv kev koom tes nrog Mayo Clinic
Cov kev pab cuam COVID-19
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia) Sij hawm
COVISTIX™ (kev kuaj mob) FDA EUA
COVIMARK™ (kev kuaj mob) FDA EUA
VIREX (kev kuaj mob) PH III
COVISHIELD™ (kev kho mob) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COV-MSC) Ph III
Mpro Inhibitor (qhov ncauj ntsiav tshuaj) Ph II
Omicron mRNA tshuaj tiv thaiv Peb muaj
immunotherapy
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia) Sij hawm
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Peb muaj
FUJOVEE™ (Abivertinib) Peb muaj
FUJOVEE™ (Abivertinib) Peb muaj
FUJOVEE™ (Abivertinib) Peb muaj
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Cov qog nqaij hlav) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Ntau Myeloma, T-ALL, thiab esophageal) Ph I
Seprehvec™ oncolytic virus (Cov qog nqaij hlav; CNS qog) PH I
BCMA ADC (Liquid Tumors) Peb muaj
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
mob
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia) Sij hawm
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Tso Cai FDA
Gloperba® 1.8% Kev kho mob ntawm Gout (Qhov ncauj) Tso Cai FDA
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Delayed Burst Low Dose Naltrexone) Peb muaj
RTX (resiniferatoxin) Kev txhaj tshuaj Epidural Ph II
RTX (resiniferatoxin) Intra-articular txoj kev Ph II
Lymphatic xa khoom
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia) Qis II
Sofusa® tiv thaiv TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I